EFFET OF COMBINATION OF HPMC AND CARBOPOL 934P ON THE PROPERTIES OF THE GASTRIC FLOATING TABETS OF TIMOLOL MALEATE by R, Narayana Charyulu
Narayana et al                                         Journal of Drug Delivery & Therapeutics; 2013, 3(4), 20-25    20 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
Available online at http://jddtonline.info 
RESEARCH ARTICLE 
EFFET OF COMBINATION OF HPMC AND CARBOPOL 934P ON THE PROPERTIES OF 
THE GASTRIC FOATING TABETS TIMOLOL MALATE 
Charyulu Narayana R*, Girish S K, Amit B Patil. 
Department of Pharmaceutics, Nitte Gulabi Shetty Memorial Institute of Pharmaceutical Sciences, Deralakatte, Mangalore, 
INDIA-575 018 
*corresponding Author’s Email: charyulun@yahoo.co.in 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION: 
Timolol maleate is a non-selective beta-adrenergic 
receptor blocker, prescribed in antihypertensive, 
antiarrhythmic and migraine. Timolol maleate is rapidly 
absorbed on oral administration with peak plasma 
concentration within 1-2 h. Plasma half-life of Timolol 
maleate is 2.5-4 h.  The oral bioavailability is 50% - 60% 
due to extensive metabolism in liver
1
. Hence an attempt is 
been made to formulate a gastro retentive delivery system 
for timolol maleate that can not only avoid its metabolism 
in liver but also enhance the bioavailability. The advantage 
of floating drug delivery system is that it retains the drug 
in gastric environment and improvises sustain delivery of 
drugs that have an absorption window in a particular 
region of the gastrointestinal tract. Hence the aim is to 
formulate a timolol maleate gastric floating delivery 
system that will release the drug continuously at 
predetermined rate before it reaches the absorption 
window thus ensuring optimal bioavailability, improved 
patient compliance and reduced dose frequency
2
.  
The gastric floating drug delivery systems have a bulk 
density less than gastric fluid and so remain buoyant in the 
stomach without affecting the gastric emptying rate for a 
prolonged period of time. This also results in an increased 
gastric retention time and better control of fluctuations of 
plasma drug concentration.  
MATERIALS AND METHODS: 
MATERIALS: 
Timolol maleate was obtained as a gift sample from Ajanta 
Pharma, Mumbai. HPMC grade K4M, K15M, K100M and 
carbopol 934P was a gift sample from Merck Chemicals, 
Germany. Sodium bicarbonate, citric acid, PVPK30, talc 
and magnesium stereate purchased from Reachem 
chemicals, Mumbai. All the chemicals used were of 
analytical grade. 
METHODS: 
1. Formulation of timolol maleate floating tablet: 
The formulation was prepared according to the principle of 
effervescent technique, in which all the ingredients were 
weighed accurately as per the formulation Table 1. Initially 
a powder mixture of timolol maleate, HPMC grade K4M, 
K15M, K100M, carbopol 934P, Micro crystalline cellulose 
(MCC), sodium bicarbonate, citric acid and PVP K30 was 
prepared in a clear and dry mortar and pestle, then passed 
through sieve No #80. Later magnesium stereate and talc 
were added as lubricant and glident respectively. An 
appropriate amount of the mixture was weighed and fed 
manually into the die of rotary single punch tablet machine 
using 8.5 mm punch to get tablets of average weight 330 
mg.  The punched tablets were wrapped in aluminium foil 
and stored in an air tight pouch in a controlled 
environment of temperature and humidity until further 
studies
3
. 
2. EVALUATION OF TIMOLOL MALEATE 
FLOATING TABLETS: 
Evaluation was performed to assess the pre-compression 
properties of the powder blend and post-compression 
properties of developed gastric floating tablet 
formulations. 
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2.1. Pre-compression evaluation parameters of powder 
blends: 
Angle of repose: 
The angle of repose of powder blend was determined by 
the funnel method. Accurately weighed powder blends 
were filled in the funnel. The height of the funnel was 
adjusted in such a way that the tip of the funnel just 
touches the apex of the powder blend. The powder blend 
was allowed to flow through the funnel freely on to the 
surface. The diameter of the powder cone was measured 
and angle of repose was calculated using the following 
equation
4
. 
tan θ = h/r 
θ = tan-1 (h/r) 
Where, 
θ = angle of repose; h= height of the pile; r= 
radius of the cone made by powder blend  
 
Table 1: Formulation of timolol maleate gastric floating tablet 
Ingredients 
 
Formulation code 
F1 
(mg) 
F2    
(mg) 
F3    
(mg) 
F4    
(mg) 
F5    
(mg) 
F6    
(mg) 
F7    
(mg) 
F8    
(mg) 
F9    
(mg) 
HPMC K15M 150 120 120 - - - - - - 
HPMC K4M - - - 150 120 120 - - - 
HPMC K100M - - - - - - 150 120 120 
Carbopol 934P - 20 30 - 20 30 - 20 30 
Timolol maleate 25 25 25 25 25 25 25 25 25 
Sodium 
bicarbonate 
60 60 60 60 60 60 60 60 60 
Citric acid 20 20 20 20 20 20 20 20 20 
MCC 60 70 60 60 70 60 60 70 60 
PVP K30 10 10 10 10 10 10 10 10 10 
Talc 2 2 2 2 2 2 2 2 2 
Magnesium 
stearate 
3 3 3 3 3 3 3 3 3 
Total 330 330 330 330 330 330 330 330 330 
 
Bulk density: 
Both loose bulk density and tapped bulk density were 
determined. A quantity accurately equal to 10 g of powder 
from each formulation was introduced into a 10 ml 
measuring cylinder. Initial volume was observed, the 
cylinder was allowed to tap. The tapping was continued 
until no further change in volume was noted. Bulk density 
was calculated by using formula
4
. 
Bulk density = M / V0 
Where, 
M = mass of powder. V0 = bulk volume of the powder. 
Tapped density = M / Vt 
Where, 
M = mass of powder, Vt = tapped volume of the powder. 
 Compressibility Index (Carr’s consolidation Index): 
Another indirect method of measuring flow from bulk 
densities was developed by Carr. The percentage 
compressibility of a powder is a direct measure of the 
potential powder arch or bridge strength and stability. It is 
calculated according to the following equation
4
.  
             ( )   
(                          )
              
        
2.2. Post-compression evaluation parameters of timolol 
maleate gastric floating tablet  
Thickness test: 
Thickness test was performed by measuring the thickness 
of the tablet at different positions using a standard 
calibrated screw gauge meter. The thickness was expressed 
in mm. Three tablets from each formulation were selected 
randomly
5
. 
Hardness test: 
The hardness of the tablets was determined using Pfizer 
hardness tester. It is expressed in kg/cm
2
. Three tablets 
from each formulation were selected randomly
5
. 
Friability: 
Roche friabilator was used for testing the friability of the 
tablets. Twenty tablets were weighed accurately and 
placed in the tumbling apparatus that revolves at 25 rpm. 
After 4 min the tablets were weighed and the percentage 
loss in tablet weight was determined
5
. 
Weight variation test: 
Twenty tablets were weighed individually and the average 
weight was determined. Then percentage deviation from 
the average weight was calculated
5
. 
Drug content estimation: 
Randomly selected ten tablets were weighed and powdered 
in a mortar and pestle. Powder weighing equivalent to 330 
mg of timolol maleate was accurately weighed and 
transferred into a 100 ml volumetric flask and dissolved in 
0.1N HCl, pH 1.2. Subsequently the solution from 
volumetric flask was filtered and suitable dilutions were 
made. These aliquots were analyzed at 275 nm using UV-
Visible spectrophotometer. The drug content of each 
sample was estimated from standard curve of 
clarithromycin using 0.1N HCl, pH 1.2
7
. 
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Swelling index: 
Swelling property of tablet was determined by placing it in 
the dissolution test apparatus, in 900 ml of 0.1 N HCL at 
37 ± 2 °C. The weight and volume reached by the matrix 
tablets over time was determined by withdrawing the 
tablets periodically from dissolution medium. The tablets 
were weighed on an analytical balance after slight blotting 
with tissue paper to remove the excess liquid. The volume 
of the tablets was obtained by measuring the thickness and 
diameter, considering a right circular cylinder form. The 
determined weight and volume were used to calculate the 
tablet density over the dissolution study. Swelling 
characteristics were expressed in terms of percentage water 
uptake (WU %) or swelling index according to the 
equation
8
. 
               (   )  
     
  
       
Where, 
Wi = initial weight of tablet, Wf = final weight of tablet 
The buoyancy lag time and the total floating time:  
Buoyancy or floating behavior studies was carried out in a 
USP Dissolution Testing Apparatus II (Paddle type) at 
paddle speed 50 rpm in 900ml 0.1 N HCl at 37 ± 0.2 °C 
for 24 h to mimic in vivo conditions. For determining the 
optimized buoyancy lag time and total floating time of the 
delivery system, various formulations prepared according 
to table 1 were studied. The time interval between the 
introduction of the tablet into the dissolution medium and 
its buoyancy to the top of dissolution medium was taken as 
floating lag time, the duration of system floatation and also 
the relative matrix integrity was observed visually
7
. 
 In vitro drug release  
The in vitro release rate of timolol maleate from floating 
tablets was determined using USP dissolution testing 
apparatus II (paddle type). The test was performed using 
900 ml of 0.1 N HCl at 37 ± 0.5 °C and 50 rpm for study. 
The amount of drug released over time was determined by 
withdrawing samples at various determined time intervals 
for 24 hrs and were replaced with fresh dissolution 
medium. The aliquots were filtered through Whattman 
filter paper Grade-1and concentration of drug was obtained 
by measuring the absorbance at 275 nm using UV-Visible 
spectrophotometer
8
. 
 
RESULTS: 
Pre-compression evaluation parameters of powder 
blends: 
The pre-compression parameters such as angle of repose, 
bulk density, tapered density and compressibility index 
were evaluated. The results of all the pre compression 
parameters were found to comply with the specification of 
IP. The results are displayed in Table 2.  
Post-compression evaluation parameters of timolol 
maleate gastric floating tablet: 
All the formulations subjected for post-compression 
characterization of morphological properties such as 
thickness, hardness, weight variation and friability test 
showed satisfactory results which were within the limits 
for all the formulation. The results of these tests are 
reported in Table 3.  
 
Table 2: Pre-compression evaluation parameters of gastric floating tablets 
Formulation code 
Angle of repose*  
± SD (θ) 
Bulk density*  
± SD (g/ml) 
Tapped density*  
± SD (g/ml) 
Compressibility index* ± 
SD (%) 
F1 18.24±0.11 0.464±0.08 0.542±0.09 15.12±0.09 
F2 19.71±0.09 0.479±0.06 0.512±0.08 18.94±0.09 
F3 20.14±0.09 0.462±0.05 0.571±0.07 18.91±0.10 
F4 18.96±0.14 0.483±0.10 0.563±0.09 14.20±0.12 
F5 20.04±0.21 0.492±0.11 0.593±0.01 17.03±0.12 
F6 20.62±0.11 0.487±0.05 0.581±0.01 16.17±0.11 
F7 19.13±0.13 0.493±0.09 0.577±0.09 14.55±0.05 
F8 20.45±0.09 0.461±0.08 0.542±0.09 15.12±0.04 
F9 22.50±0.09 0.487±0.07 0.581±0.10 16.17±0.05 
*Each reading is an average of 6 determinants 
Table 3: Post-compression parameters of gastric floating tablets 
Formulation code 
Average thickness* 
 ± SD (mm) 
Hardness*  
± SD (kg/cm2) 
Weight variation* 
± SD (mg) 
Percentage friability 
F1 4.4±0.001 5.1±0.2 328 ±2.43 0.48% 
F2 4.5±0.004 5.4±0.8 327±2.40 0.39% 
F3 4.6±0.003 5.2±0.9 330±2.71 0.21% 
F4 4.8±0.001 5.3±0.8 332±2.41 0.28% 
F5 4.5±0.002 5.1±0.5 328±2.74 0.34% 
F6 4.6±0.003 5.2±0.6 329±2.49 0.42% 
F7 4.4±0.002 5.4±0.7 329±2.33 0.19% 
F8 4.3±0.005 5.3±0.9 328±2.98 0.35% 
F9 4.4±0.006 5.1±1.1 327±2.64  0.36 % 
*Each reading is an average of 6 determinants 
Buoyancy studies: From the results it can be noted that the formulations 
containing different grades of HPMC polymer only such as 
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F1, F4 and F7 showed good buoyancy lag time less than 
10 sec, but it did not float for more than 9 h. The batch 
containing HPMC polymer with Carbopol 934P in 
concentration of 20 mg and 30 mg such as F2, F3, F5, F6, 
F8 and F9 showed poor lag time less than 2 mins but 
exhibited good total floating time of more than 12 h. The 
results are reported in Table 4.  
Drug content: 
The drug content varied from 91.20 ± 0.44 % to 100.01 ± 
0.04 % which was within the required limits of ± 2% 
according to IP. The results of the tests are given in Table 
4.
 
Table 4: Buoyancy lag time and total floating time of gastric floating tablets 
Formulation code Buoyancy Lag time* ± SD (sec) Total floating   time (h) Percentage Drug content* ± SD 
F1 8    ±   1.2 ≤ 9 97.14±0.15 
F2 48  ±   2.8 >12 96.53±0.23 
F3 67  ±   3.3 >12 93.72±0.12 
F4 6    ±   2.3 ≤ 9 97.95±0.22 
F5 51  ±   4.5 >12 95.88±0.34 
F6 72  ±   6.6 >12 100.01±0.4 
F7 7    ±   3.1 ≤ 9 97.91±0.23 
F8 40  ±   2.7 >12 92.40±0.17 
F9 54  ±   1.8 >12 91.2±0.44 
*Each reading is an average of 6 determinants. 
 
Swelling index studies: 
The swelling index studies performed on all the 
formulations showed that the swelling index of HPMC 
K15M, K4M and K100M was found to be 184.3, 164.3 and 
278.8 at the end of 8 h respectively. Whereas formulation 
F2,  F3, F5, F6, F8 and F9 containing HPMC K15M, K4M 
and K100M with 20 and 30 mg of Carbopol 934P was 
245.6, 261.7, 228.7, 258.3, 296.3 and 311.8 respectively at 
the end of 9 h.  The results are shown in Table 5. 
 
Table 5: Swelling index studies 
Time (h) F1* F2* F3* F4* F5* F6* F7* F8* F9* 
0.5 
32.81 
±0.08 
51.23 
±0.19 
63.71 
±0.09 
31.85 
±0.06 
45.22 
±0.02 
56.35 
±0.05 
64.13 
±0.15 
78.38 
±0.11 
80.19 
±0.19 
1 
48.43 
±0.20 
75.32 
±0.03 
81.42 
±0.03 
40.64 
±0.17 
60.34 
±0.14 
78.65 
±0.13 
89.3 
±0.01 
110.4 
±0.05 
116.3 
±0.29 
2 
64.52 
±0.01 
108.8 
±0.12 
117.1 
±0.19 
60.71 
±0.09 
89.65 
±0.12 
110.8 
±0.09 
119.4 
±0.06 
134.5 
±0.08 
143.2 
±0.06 
3 
101.5 
±0.15 
158.3 
±0.17 
176.1 
±0.14 
94.31 
±0.07 
108.9 
±0.13 
154.9 
±0.04 
169.1 
±0.16 
166.6 
±0.14 
176.8 
±0.07 
4 
143.7 
±0.22 
175.3 
±0.10 
201.3 
±0.15 
132.1 
±0.05 
148.1 
±0.14 
188.1 
±0.03 
184.2 
±0.11 
189.7 
±0.15 
199.1 
±0.14 
5 
158.6 
±0.19 
195.1 
±0.11 
223.6 
±0.15 
141.7 
±0.01 
174.4 
±0.12 
213.3 
±0.08 
213.4 
±0.19 
217.9 
±0.13 
227.3 
±0.13 
6 
169.2 
±0.16 
220.3 
±0.09 
246.7 
±0.11 
154.8 
±0.07 
193.3 
±0.17 
236.4 
±0.11 
246.3 
±0.13 
234.1 
±0.19 
249.2 
±0.15 
7 
175.5 
±0.17 
236.4 
±0.05 
254.7 
±0.14 
158.1 
±0.14 
210.1 
±0.05 
247.2 
±0.14 
269.7 
±0.12 
256 
±0.11 
267.5 
±0.19 
8 
184.3 
±0.16 
241.7 
±0.06 
258.9 
±0.01 
164.3 
±0.11 
221.6 
±0.08 
253.1 
±0.18 
278.8 
±0.09 
279.1 
±0.19 
284.5 
±0.12 
9  
245.6 
±0.09 
261.7 
±0.02 
 
228.7 
±0.02 
258.3 
±0.16 
 
296.3 
±0.09 
311.8 
±0.07 
*Each reading is an average of 6 determinants. 
In vitro drug release: 
The in vitro drug release data for Formulation F1, F4 and 
F7 was found to be above 95% drug release in 8 h 
containing only different grades of HPMC and 90 – 95% 
in 12 h for formulation F2, F3, F5, F6, F8 and F9 
containing different grades of HPMC with carbopol 934P. 
The results are given in fig. 1. 
Drug Release Kinetics: 
The various drug release kinetic models were studied for 
the value of correlation coefficient. The best linearity was 
found in Higuchi’s plot as its linear regression is nearer to 
‘1’ indicating the release of drug from matrix as a square 
root of time. The ‘n’ values which characterizes diffusion 
release mechanism by Krospeyer peppas model was found 
to be in the range of 0.45 to 0.63. (Table 6).
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Figure 1:  In vitro drug release profile of timolol maleate gastric floating tablet. 
Table 6: Drug Release kinetics profile of dissolution studies 
Formulation code 
Kinetic models 
 
Zero order First  order Higuchi order Korsmeyer-peppas order 
F1 
y = 11.393x + 18.559 
R² = 0.9212 
y = -0.0859x +1.4951 
R² = 0.138 
y = 36.326x - 1.6586 
R² = 0.9962 
y = 0.9776x + 1.1816 
R² = 0.4513 
F2 
y = 8.4222x + 11.599 
R² = 0.9613 
y = -0.0272x +1.5656 
R² = 0.0467 
y = 26.179x - 2.1993 
R² = 0.988 
y = 0.9056x + 1.0774 
R² = 0.4586 
F3 
y = 6.6968x + 14.636 
R² = 0.9557 
y = -0.0163x +1.5511 
R² = 0.0178 
y = 26.084x - 3.6259 
R² = 0.9939 
y = 0.9264x + 1.0459 
R² = 0.4851 
F4 
y = 11.286x + 21.074 
R² = 0.8956 
y = -0.1114x +1.5182 
R² = 0.1968 
y = 36.432x + 0.2845 
R² = 0.9928 
y = 0.9662x + 1.203 
R² = 0.4362 
F5 
y = 7.2149x + 15.559 
R² = 0.9552 
y = -0.0377x +1.5894 
R² = 0.0827 
y = 28.07x - 4.0487 
R² = 0.9912 
y = 0.874x + 1.0839 
R² = 0.5636 
F6 
y = 6.9517x + 13.299 
R² = 0.9719 
y = -0.024x + 1.5793 
R² = 0.0361 
y = 26.746x - 4.9501 
R² = 0.9863 
y = 0.866x + 1.0599 
R² = 0.5695 
F7 
y = 11.241x + 15.559 
R² = 0.9425 
y = -0.0514x +1.4665 
R² = 0.0577 
y = 35.383x - 3.6081 
R² = 0.9933 
y = 0.9914x + 1.1477 
R² = 0.4727 
F8 
y = 6.4249x + 14.039 
R² = 0.964 
y = -0.011x + 1.5513 
R² = 0.0081 
y = 24.886x - 3.1854 
R² = 0.9915 
y = 0.8518x + 1.0543 
R² = 0.5656 
F9 
y = 6.1067x + 9.8305 
R² = 0.9827 
y = -0.0535x +2.0016 
R² = 0.965 
y = 23.276x - 5.7325 
R² = 0.9787 
y = 0.8761x + 0.9799 
R² = 0.6137 
 
Stability studies 
Accelerated stability studies were conducted to observe 
any change in colour, appearance and drug content test at 
room temperature and oven temperature (40±2 °C) 
buoyancy lag time for a period of eight weeks. There was 
no significant colour and drug content change observed at 
the end of eight weeks in all the formulations.  
DISCUSSION: 
The aim of the present research was to formulate gastric 
floating tablets of timolol maleate by using three different 
grades of HPMC polymer (K15M, K4M and K100M) alone 
and then by combining these HPMC polymers individually 
with two different concentration (6% and 9%) carbopol 
934P and study the effect of carbopol 934P on the different 
properties of the gastric floating tablet. Hence three 
formulations of each grade of HPMC polymer with and 
without carbopol 934P were prepared yielding a total of 
nine formulations. 
The characterization was carried out in two stages i.e. pre-
compression and post-compression evaluation parameters. 
The pre-compression evaluation parameters comprised of 
powder properties like angle of repose, bulk density, 
tapered density and compressibility index which was done 
to ensure that the mixture of powder possessed the 
necessary characteristics to undergo compression. The 
results of the pre-compression parameters showed that the 
powder mixture of all the nine formulations were well 
within the limits as prescribed in IP, indicating its 
suitability to undergo compression. The post-compression 
parameters were carried out in two stages, namely 
morphological and physico-chemical evaluation. The post-
compression morphological characteristics included 
thickness, hardness, weight variation and friability test 
which were carried out under standard controlled 
environment. According to the results of Table 3, it can be 
interpreted that all the nine formulations showed 
satisfactory results which were within the limits prescribed 
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by IP. The post-compression physico-chemical 
characteristics included buoyancy studies, swelling time, 
in vitro drug release, drug release kinetics and stability 
studies.  The buoyancy studies reviled that formulation F1, 
F4 and F7 which contained HPMC K15M, K4M and 
K100M showed buoyancy lag time less than 10 sec and 
total floating time of ≤ 9 h when compared to formulations 
F2, F3, F5, F6, F8 and F9 with buoyancy lag time less than 
2 min and total floating time more than 12 h. Increased 
buoyancy lag time and satisfactory total floating can be 
attributed to the presence of carbopol 934P in different 
concentration. 
Optimum swelling index was seen for tablets of batch F8 
containing 120 mg of HPMC K100M and 20 mg of 
Carbopol 934P as compared to other formulations.  The 
nominal viscosity of F8 was found to be more than 
1,04,120 cps. Thus, the viscosity of the polymer had major 
influence on swelling process, matrix integrity, as well as 
floating capability, hence from the results of Table 5 it can 
be concluded that linear relationship exists between 
swelling process and viscosity of polymer. Thus swelling 
index showed the following order HPMC K100M > HPMC 
K15M > HPMC K4M i.e. F7 > F1 > F4; with addition of 
carbopol 934P there was further increase in the swelling 
property but the order remained same i.e. F9 > F8 > F3 > 
F6 > F2 > F5.  
The formulation F1, F4 F7 containing polymer HPMC 
K15M, K4M and K100M in 30% concentration floated for 
≤ 9 h but later it get disintegrated. The formulation 
containing Carbopol 934P with concentration of 6% and 
9% are F2, F3, F5, F6, F8, F9 shown total floating time 
more than 14 h without any disintegration or erosion. A 
perusal to figure 1, it can be concluded that combination of 
anionic carbopol 934P and non ionic HPMC polymer 
produce synergistic inclusion in viscosity which could be 
due to H-bonding  between carboxyl group of carbopol and 
OH group of HPMC that lead to stronger cross linking  
between two  polymer  and retarding the drug release. 
The in vitro drug release data for Formulation F1, F4 and 
F7 was found to be above 95% in 8 h. Improvement in the 
drug release was seen by including 6% carbopol 934P in 
Formulation F2, F5 and F8 showing in vitro drug release 
between 90 – 95% in 12 h. Carbopol acted as drug release 
retarding agent, by swelling and forming colloidal 
mucilage that may help resist disintegration of gastric 
floating tablet in gastric fluid. By increasing the 
concentration of carbopol 934P to 9% as in case of F3, F6 
and F9 formulations, the drug release was less than 90% in 
12 h which proved to be optimum concentration of 
polymer and gas generating agent. Among all the 
formulations prepared, formulation F5 exhibit optimum 
drug release 94.2 % in 12 h with buoyancy lag time of 51 
sec. 
The drug release kinetic data showed best linearity in 
Higuchi’s plot as its linear regression was nearer to ‘1’ 
indicating the release of drug from matrix as a square root 
of time. This model is widely used when the release 
mechanism is not well known or when more than one type 
of release phenomenon was involved. The ‘n’ values can be 
used to characterize diffusion release mechanism by 
Krospeyer peppas model. The ‘n’ value for all formulations 
was found to be in the range of 0.45 to 0.63 which indicates 
that the release approximates non-fickian diffusion 
mechanism. Hence combination of diffusion and erosion 
can be considered as mechanism of drug release from the 
formulations. 
Accelerated stability studies showed that there was no 
significant change in colour, appearance and/or drug 
content at room temperature and oven temperature. And 
also no changes in buoyancy lag time after a period of 
eight weeks in all the 9 formulations. This indicated good 
stability of the prepared formulations. 
CONCLUSION 
The effervescent-based floating drug delivery was a 
promising approach to achieve in vitro buoyancy. The 
addition of gel-forming polymer HPMC (K100, K15M, 
K4M) with carbopol 934P and gas-generating agent 
sodium bicarbonate along with citric acid was essential to 
achieve in vitro buoyancy. Carbopol 934P has given extra 
adhesion property and helped to maintain the integrity of 
the floating tablet. The drug release from the timolol 
maleate floating tablets was sufficiently sustained and non-
Fickian transport of the drug from tablets was confirmed. 
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